Healthcare · NIFTY 500

Gland Pharma Limited

NSEGLAND BSE543245 ISININE068V01023 SeriesEQ Listed on NSE · BSE

₹3,308.70 +44.80 (+1.37%) Updated 12 Nov, 7:17 pm IST

Open chart Back to screener

Price, daily close+65.79% in a year

Today

Open: ₹3,268.50
Prev close: ₹3,263.90
Day high: ₹3,347.00
Day low: ₹3,268.50
Volume: 2.24 L
Value traded: ₹74.25 Cr
Upper circuit: ₹3,916.60
Lower circuit: ₹2,611.20
52W high: ₹3,308.70
52W low: ₹1,573.60
1 month: +2.94%
6 months: +65.16%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹54,597 Cr

P/E (TTM)44.15

P/B5.11

Book value / share₹647.58

EPS (TTM)₹74.94

ROE11.6%

Dividend yield0.60%

Dividend (12m)₹20.00 / share

Net margin (TTM)17.5%

Operating margin26.4%

Debt / equity0.02

Current ratio4.59

EV / EBITDA27.08

Sales growth (YoY qtr)+23.32%

Profit growth (YoY qtr)+58.29%

Sales CAGR 3Y+21.06%

Profit CAGR 3Y+9.57%

Shares16.50 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

1,545192

Dec 23

1,537192

Mar 24

1,402144

Jun 24

1,406164

Sep 24

1,384205

Dec 24

1,425187

Mar 25

1,506215

Jun 25

1,487184

Sep 25

1,695261

Dec 25

1,743367

Mar 26

1,800317

Jun 26

1,834291

Sep 26

Revenue · QoQ (vs last quarter)

—-0.5%-8.8%+0.3%-1.5%+3.0%+5.7%-1.2%+14%+2.8%+3.3%+1.9%

Revenue · YoY (vs a year ago)

————-10%-7.3%+7.4%+5.8%+22%+22%+20%+23%

Net profit · QoQ (vs last quarter)

—+0.3%-25%+14%+25%-8.9%+16%-15%+42%+40%-14%-8.3%

Net profit · YoY (vs a year ago)

————+6.7%-3.1%+50%+12%+28%+97%+47%+58%

RevenueNet profitLine = trend

11.65

Dec 23

11.68

Mar 24

8.73

Jun 24

9.93

Sep 24

12.42

Dec 24

11.32

Mar 25

13.08

Jun 25

11.15

Sep 25

15.87

Dec 25

22.23

Mar 26

19.22

Jun 26

17.62

Sep 26

EPS (₹) · YoY (vs a year ago)

————+6.6%-3.1%+50%+12%+28%+96%+47%+58%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	1,545	1,537	1,402	1,406	1,384	1,425	1,506	1,487	1,695	1,743	1,800	1,834
Other income	37.4	42.1	51.4	59.7	58.5	44.0	57.5	84.2	63.2	111	61.2	69.0
Total income	1,583	1,580	1,453	1,465	1,443	1,469	1,563	1,571	1,759	1,854	1,861	1,903
Raw material	464	575	462	486	437	588	557	558	530	594	588	641
Purchases	6.4	6.8	6.6	2.7	2.1	3.1	0.9	1.9	1.5	2.3	1.9	3.1
Employee cost	345	352	356	330	343	373	408	385	424	412	444	412
Other expenses	244	228	218	204	219	216	209	234	260	227	243	268
Total expenses	1,299	1,281	1,235	1,209	1,143	1,181	1,250	1,287	1,372	1,348	1,427	1,472
Operating profit	356	359	264	297	360	348	368	314	411	513	489	484
OPM %	23.1%	23.3%	18.9%	21.1%	26.0%	24.4%	24.4%	21.1%	24.2%	29.4%	27.2%	26.4%
Finance cost	5.3	10.0	5.6	6.1	22.8	7.5	11.5	7.8	3.9	10.0	4.4	7.1
Depreciation	105	92.6	92.0	93.8	96.3	95.8	101	106	108	109	111	115
Exceptional items	—	—	—	—	—	—	—	—	-24.3	—	—	—
Profit before tax	283	298	218	257	299	288	313	284	362	506	435	431
Tax	91.3	106	74.5	93.2	94.6	102	97.3	100	101	139	118	140
Net profit	192	192	144	164	205	187	215	184	261	367	317	291
Profit to shareholders	192	192	144	164	205	187	215	184	261	367	317	291
EPS (₹)	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.23	19.22	17.62

Profit & loss

Results for each year

6 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

3,4631,302997

FY21

4,4011,5101,212

FY22

3,625968781

FY23

5,6651,333772

FY24

5,6171,269699

FY25

6,4311,6051,027

FY26

Revenue · YoY (vs a year ago)

—+27%-18%+56%-0.9%+14%

Net profit · YoY (vs a year ago)

—+22%-36%-1.1%-9.6%+47%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	3,463	4,401	3,625	5,665	5,617	6,431
Other income	135	224	240	170	214	316
Total expenses	2,263	3,006	2,754	4,702	4,767	5,258
Employee cost	311	339	403	1,257	1,402	1,629
Operating profit	1,302	1,510	968	1,333	1,269	1,605
OPM %	37.6%	34.3%	26.7%	23.5%	22.6%	25.0%
Finance cost	3.4	5.2	7.4	26.2	42.0	33.3
Depreciation	98.8	110	147	345	378	424
Profit before tax	1,335	1,619	1,055	1,133	1,063	1,465
Tax	338	407	274	360	364	437
Tax rate %	25.3%	25.1%	25.9%	31.8%	34.3%	29.9%
Net profit	997	1,212	781	772	699	1,027
Profit to shareholders	997	1,212	781	772	699	1,027
Net margin %	28.8%	27.5%	21.5%	13.6%	12.4%	16.0%
EPS (₹)	62.99	73.64	47.43	46.89	42.40	62.28

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

7,9593.81,909

Mar 23

8,724320357

Mar 24

9,1512692,556

Mar 25

10,3582433,359

Mar 26

10,6862203,441

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+9.6%+4.9%+13%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	7,959	8,724	9,151	10,358	10,686
Long-term borrowings	3.3	107	77.7	69.9	63.4
Short-term borrowings	0.6	213	192	173	156
Total borrowings	3.8	320	269	243	220
Current liabilities	729	1,398	1,565	1,608	1,714
Fixed assets (PPE)	1,559	3,541	3,751	4,052	3,970
Inventories	1,945	1,655	1,685	1,744	1,829
Trade receivables	871	1,559	1,517	1,891	1,927
Cash & equivalents	1,909	357	2,556	3,359	3,441
Current assets	6,901	5,645	6,783	7,527	7,872
Total assets	8,778	10,661	11,225	12,511	12,927
Debt / equity	0.00	0.04	0.03	0.02	0.02

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

791-1,00334.9

FY22

3641,20814.9

FY23

997-1,757-799

FY24

9151,705-433

FY25

1,031138-417

FY26

Operations · YoY (vs a year ago)

—-54%+174%-8.2%+13%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	791	364	997	915	1,031
Cash from investing	-1,003	1,208	-1,757	1,705	138
Cash from financing	34.9	14.9	-799	-433	-417
Spent on fixed assets	-511	-221	-390	-385	-491
Free cash flow	279	143	607	530	541
Net cash flow	-177	1,587	-1,560	2,186	752

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

57.9%Dec 23

57.9%Mar 24

51.8%Jun 24

51.8%Sep 24

51.8%Dec 24

51.8%Mar 25

51.8%Jun 25

51.8%Sep 25

51.8%Dec 25

51.8%Mar 26

51.8%Jun 26

45.8%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

45.8%promoter

Promoter & group: 45.75%
Public (FIIs, mutual funds, retail…): 54.25%
Promoter change, last quarter: -6.02 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Dividend - Rs 20 Per ShEx 11-Aug-2026
Dividend - Rs 18 Per ShareEx 14-Aug-2025
Annual General Meeting/Dividend - Rs 20 Per ShareEx 16-Aug-2024
Annual General MeetingEx 06-Aug-2021

Board meetings

GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financi…06-Nov-2026
the financial results for the period ended September 30, 202606-Nov-2026
GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 10-Aug-2026 to inter-alia consider and approve the Unaudited Financi…10-Aug-2026
the financial results for the period ended Jun 30, 202610-Aug-2026
the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.15-May-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates12 Nov
Giving guarantees/indemnity/ becoming a surety for third party12 Nov
Appointment9 Nov
Copy of Newspaper Publication7 Nov
Shareholders meeting6 Nov
Analysts/Institutional Investor Meet/Con. Call Updates6 Nov
Investor Presentation6 Nov

Latest news

Gland Pharma Share PriceUpstox · 8 Nov, 12:59 am Gland Pharma shares rally 8% to hit 4-year-high post strong Q2; what brokerages say, check target pricesMoneycontrol.com · 9 Nov, 6:19 pm Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell' - CNBC TV18LinkedIn · 9 Nov, 12:57 pm Gland Pharma shares hit 52-week high; jump 7% despite market sell-off | Will rally continue after 93% YTD rise?TradingView · 9 Nov, 1:34 pm Why Gland Pharma Share Price Is Rallying? Check 3 Key Reasons Behind the SurgeDalal Street Investment Journal · 9 Nov, 10:37 am Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · 9 Nov, 12:23 pm Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'CNBC TV18 · 9 Nov, 12:46 pm Divis Laboratories, Gland Pharma, Sai Life Sciences shares hit 52-week highs; here's whyBusiness Today · 9 Nov, 11:35 am

About

About Gland Pharma Limited

Gland Pharma Limited is listed on the NSE under the symbol GLAND and belongs to the Healthcare sector.

Company details

Company name: Gland Pharma Limited
NSE symbol: GLAND
BSE scrip code: 543245
ISIN: INE068V01023
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 20 Nov 2020
Face value: ₹1 per share
Market lot: 1 share
Shares issued: 16.50 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Chair: Srinivas Sadu
Headquarters: Hyderabad, Telangana, India
Registered address: Plot No.11& 84,TSIIC, Phase-IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, Telangana, India, 502307
Founded: 1978
Employees: 4,332
Financial year: April to March
Results basis: Consolidated
Website: glandpharma.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Gland Pharma Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers